Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Follicular × abexinostat × 1 year × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 2 Sarcoma 1 Oligodendroglioma 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Disease Progression 1 Carcinoma, Renal Cell 1 Astrocytoma 1

Interventions

Rituximab 47 Cyclophosphamide 47 Lenalidomide 39 fludarabine 24 obinutuzumab 23 Bendamustine Hydrochloride 18 Magnetic Resonance Spectroscopy 17 fludarabine phosphate 15 Vincristine 15 Prednisone 15 Specimen Handling 14 Doxorubicin 14 zanubrutinib 12 Biopsy 12 ibrutinib 11 tazemetostat 10 venetoclax 9 Whole-Body Irradiation 8 pembrolizumab 7 Peripheral Blood Stem Cell Transplantation 7 Etoposide 7 Mycophenolic Acid 6 CT-P10 6 axicabtagene ciloleucel 5 R-CHOP protocol 5 tisagenlecleucel 4 Therapeutics 4 Stem Cell Transplantation 4 Radiotherapy 4 Prednisolone 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03600441 2025-04-10

FORERUNNER

Xynomic Pharmaceuticals, Inc.

Phase 2 Active not recruiting

Lymphoma, Follicular, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡